The HER2 testing conundrum

  title={The HER2 testing conundrum},
  author={Malorye Allison},
  journal={Nature Biotechnology},
Testing tempest Personalized medicine proponents point to Herceptin as a paradigm changer: the monoclonal antibody targeting HER2 (also referred to as HER2/neu and ERBB2) evens the playing field for breast cancer patients overexpressing HER2, whose tumors are typically more aggressive. But testing was problematic from the start, due to either sloppy execution or complex tumor biology. “Giving Herceptin early improves outcome so dramatically that it is an absolute tragedy to miss patients who… CONTINUE READING
29 Citations
0 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 29 extracted citations

Similar Papers

Loading similar papers…